Dr. Wayne Grover Brisbane, MD

Dr. Brisbane practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Brisbane's NPI, 1346583176, was assigned on March 29, 2013. Dr. Brisbane graduated from Loma Linda University School Of Medicine in 2013. Dr. Brisbane holds California license A161053.

Dr. Brisbane's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Brisbane's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Brisbane is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Brisbane to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brisbane practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Brisbane's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Brisbane is board certified in urology by the American Board of Urology. Dmand AI has Dr. Brisbane's licenses on file in 4 states: California, Florida, Washington and Alaska.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney removal surgery, prostate surgery, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Brisbane treats.

CMS data shows 968 Medicare services from Dr. Brisbane across 13 procedure codes in 2024, for 372 Medicare patients. Medicare paid $142,694 for them.

CMS counts 372 Medicare patients who saw Dr. Brisbane in 2024. The largest group is 65 to 74, with 227 patients. 75% of them have cancer, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Brisbane's median patient age at 69, with 2% women.

In 2024, Dr. Brisbane wrote 266 Medicare Part D claims for 104 patients. 84% of them were for generic drugs. CMS names the drug for 203 of them, across 8 drugs with 11 or more claims each, at $84,995 in total drug cost. In 2023, CMS named 138 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Brisbane for performance year 2024, reported as part of a group. Dr. Brisbane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brisbane as offering telehealth. CMS counts 16 procedures of prostate resection by Dr. Brisbane, more than 74% of the clinicians it reports for that procedure.

Dmand AI links 8 papers to Dr. Brisbane, published from 2021 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Prostatic Neoplasms, Magnetic Resonance Imaging and Ultrasonography. Dr. Brisbane has published most often in Annu Int Conf IEEE Eng Med Biol Soc. Dr. Brisbane's most frequent co-authors are Adam Kinnaird, MD, PhD, Ely Richard Felker, MD and Kai Zhao, MD.

Dmand AI links Dr. Brisbane to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 107 general payments to Dr. Brisbane from 14 drug and device companies from 2016 to 2025. Grants make up the largest share, 56% of the total. Boston Scientific Corporation paid the most, $89,210.

Dr. Brisbane graduated from Loma Linda University School Of Medicine in 2013.

Dr. Brisbane is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.